Drugs / Vusolimogene Oderparepvec
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06216938 | Mar 2024 → Mar 2028 expected | melanoma | Yana Najjar | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06898970 | Jan 2026 → Oct 2029 expected | angiosarcoma | Varun Monga, MBBS | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06264180 | Jul 2024 → Sep 2030 expected | melanoma | Replimune, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-03 | Replimune, Inc. | Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1 replimune.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vusolimogene Oderparepvec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06264180 ↗ |
| Known as | RP1 | “Vusolimogene oderparepvec (RP1)” NCT06216938 ↗ |
| Route | Other | “is administered by intratumoral injection” NCT06216938 ↗ |